TO THE EDITOR:

Survival estimates of adults with sickle cell disease (SCD) in high-income countries are limited because of the absence of prospective cohorts of young adolescents followed to and through adulthood. Recently, Gardner et al described a cohort of 712 adults with SCD (16-80 years of age) at King’s College Hospital (London, U.K.) from 2004 to 2013 that included 5268 patient-years of observation, and the median observation per patient was 8 years. The estimated median age of survival was 67 years for 450 adults with HbSS/HbSβ0, an age that is significantly greater than that observed in a similar study in the United States reporting a median survival of 44.7 years for 132 adults with HbSS/HbSβ0/HbSD.

To address whether the higher median survival of adults with SCD living in London compared with adults with SCD...

You do not currently have access to this content.